51st week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150359867 | OVARIAN CANCER VACCINES AND VACCINATION METHODS - Compositions of multipeptide vaccines including tumor associated antigens, compositions of antigen presenting cell (e.g., dendritic cell) based vaccines presenting epitopes from tumor associated antigens, and methods of making same, are provided herein. Also, disclosed are methods for treating ovarian cancers using such vaccines. | 2015-12-17 |
20150359868 | Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine - The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation. | 2015-12-17 |
20150359869 | METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION - Disclosed herein are nucleic acid-based vaccines against malaria and other conditions. A DNA construct comprising nucleic acid encoding one or more pathogen proteins, such as malaria parasite proteins, nucleic acid encoding a dendritic cell ligand, and a linker polynucleotide, is administered with an adjuvant and/or by electroporation to achieve in vivo results that are not achieved with the vaccine components alone. The vaccine can also be formulated using a fusion protein expressed by the disclosed nucleic acid, in combination with an adjuvant. | 2015-12-17 |
20150359870 | IMMUNOLOGICALLY ACTIVE COMPOSITIONS - This invention provides a microparticle carrier system comprising of one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other bioactive substances with or without targeting molecules attached. In addition, the invention also provides immune modulatory compositions and methods of eliciting protective immune responses both in uninfected and infected hosts as well as the induction of immune tolerance. | 2015-12-17 |
20150359871 | IMMUNOGENIC COMPOSITIONS COMPRISING SILICIFIED VIRUS AND METHODS OF USE - It is disclosed herein that viruses coated in silica retain infectivity and the capacity to induce an immune response in an infected host. In addition, silicified virus is remarkably resistant to desiccation. Provided herein are methods of inducing a virus-specific immune response in a subject by administering to the subject an effective amount of silicified virus or silicified virus particles. Methods of enhancing a virus-specific cell-mediated immune response (such as a T cell-mediated immune response) in a subject by administering to the subject a silicified virus or silicified virus particles are also described herein. Further provided are immunogenic compositions comprising silicified virus or silicified virus particles, such as compositions useful as vaccines. The immunogenic compositions include a pharmaceutically acceptable carrier and/or an adjuvant. | 2015-12-17 |
20150359872 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 2015-12-17 |
20150359873 | USE OF A GENETICALLY MODIFIED INFECTIOUS MEASLES VIRUS WITH ENHANCED PRO-APOPTOTIC PROPERTIES (MV-DELTAC VIRUS) IN CANCER THERAPY - The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumour or cancer conditions, and for the preparation of agents or compositions for such treatment. | 2015-12-17 |
20150359874 | VACCINE FORMULATION - The present invention relates, in general, to a method of inducing an immune response to HIV-1 in a mammal and, in particular, to a vaccine formulation suitable for use in such a method comprising an HIV-1 envelope (Env) immunogen comprising recombinant Envs with some degree of high-mannose glycan residues and a Toll-like receptor (TLR) agonist-supplemented squalene-based adjuvant. | 2015-12-17 |
20150359875 | POLYVALENT VACCINE - The disclosure generally relates to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same. | 2015-12-17 |
20150359876 | GENERATION OF BROADLY-SPECIFIC, VIRUS-IMMUNE CELLS TARGETING MULTIPLE HIV ANTIGENS FOR PREVENTIVE AND THERAPEUTIC USE - Compositions for T cell-based immunotherapy of HIV, HIV-associated malignancies, HIV-associated viral infections, or other HIV-related complications. Modified T cells that are resistant to invasion or infection with HIV, such as T-cells modified to decrease or eliminate expression of mannosyl-oligosacharide glucosidase enzyme (“MOGS”). Methods for producing such compositions by expanding HIV-specific T cells from different sources to recognize multiple HIV antigens. | 2015-12-17 |
20150359877 | Viral Vaccine Vectors - The present invention relates to a hybrid-viral vector system, in particular, but not exclusively, to a hybrid-viral vector system that can be used as a vaccine vector. | 2015-12-17 |
20150359878 | USE OF REPLICATION DEFICIENT HSV-1 AS A VACCINE VECTOR FOR THE DELI VARY OF HIV-1 TAT ANTIGEN - A vaccine for a DNA virus, especially HSV1, comprises an expression vector for HIV1 Tat, wherein the vector is an avirulent form of said DNA virus, and elicits cellular responses to cryptic epitopes of the DNA virus, as well as eliciting a detectable IgG response. | 2015-12-17 |
20150359879 | RECOMBINANT PARTICLE BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention relates to gene and protein assemblies in the form of virus-like particles and protein complexes for use as prophylactic or therapeutic vaccines, and diagnostic and R&D tools for human cytomegalovirus (HCMV) and other herpes viruses. The virus-like particles comprise one or more capsid proteins from a herpes virus or a retrovirus, three or more CMV surface proteins and optionally tegument proteins. The assemblies are prepared using a technology combining recombinant DNA with disposable cell culture and purification techniques. | 2015-12-17 |
20150359880 | DUAL ADJUVANT VACCINE COMPOSITIONS, PREPARATION AND USES - The present invention relates to vaccines comprising an effective amount of at least one antigen in a water-in-oil-in-water (WOW) emulsion and an additional adjuvant, and to the methods of preparation and uses thereof. | 2015-12-17 |
20150359881 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2015-12-17 |
20150359882 | Methods and Compositions For Treating Clostridium Difficile Associated Disease - The present invention provides methods for treating and preventing the reoccurrence of | 2015-12-17 |
20150359883 | Treatment of Carcinomas with a Combination of EGF-Pathway and Telomerase Inhibitors - A method and kit for inhibiting the proliferation of carcinoma cells are disclosed, based on a combination of an EGF pathway inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the antibody alone or the telomerase inhibitor alone. | 2015-12-17 |
20150359884 | MULTI-PHOTON ISOMERISATION OF COMBRETASTATINS AND THEIR USE IN THERAPY - Combretastatins and their use in treating conditions characterised by abnormal vasculature or cancer by irradiation of the combretastatin in situ, and kits comprising such compounds. | 2015-12-17 |
20150359885 | THERMAL THERAPEUTIC REAGENT - A thermal therapeutic reagent is provided. The thermal therapeutic reagent comprises a plurality of magnetic nanoparticles, a plurality of surfactants coating on the magnetic nanoparticles respectively, and a polar magnetic fluid for delivering the magnetic nanoparticles to a target site. Wherein, the magnetic nanoparticles are capable of being activated under a magnetic field applied at the target site. Another thermal therapeutic reagent comprising a non-polar magnetic fluid is also provided. | 2015-12-17 |
20150359886 | SYSTEM AND METHODS FOR NANOSTRUCTURE PROTECTED DELIVERY OF TREATMENT AGENT AND SELECTIVE RELEASE THEREOF - A method and nanoparticle construct provides shielded delivery of a drug or agent to a tissue or treatment site, and release of the agent may be triggered externally. Carbon nanotubes (CNTs) are filled with the therapeutic agent in a temperature sensitive gel, and release of the agent is effected by inductive heating, e.g. applying an alternating or pulsed magnetic field, or electrical field. The CNTs may be functionalized for solubility, drug absorption, responsivity to pH, enzyme catalysis, and/or ambient biological environment. Encapsulation within the nanostructure protects the intracorporal or surrounding cellular environment from the potentially toxic cargo and prevents the degradation of the cargo during delivery. By releasing at or in the target tissue extremely small amounts of the agent may achieve an effective level of treatment, as measured by cell apoptosis, tumor shrinkage or other treatment effect while safely avoiding systemic damage. | 2015-12-17 |
20150359887 | Heat-Sensitive Nanoparticle System - A heat-sensitive system comprising at least one nanoparticle bound covalently to at least one thermolabile molecule comprising an azo —N═N— functional group —N═N— in turn bound covalently to at least one active molecule selected from a fluorophore molecule and a drug is disclosed. The system converts an electromagnetic radiation into thermal energy exposed to an alternating magnetic field. Uses of the system are also disclosed. | 2015-12-17 |
20150359888 | Methods and Compositions for Restoring Homeostatic Capacity of a Subject - Methods of restoring homeostatic capacity of a subject are provided. Aspects of the invention further include compositions, systems and devices for practicing the methods. The methods and compositions described herein find use in a variety of applications. | 2015-12-17 |
20150359889 | Cardiac arrest muscle relaxant - Muscle Relaxants for Cardiac Arrest Patients | 2015-12-17 |
20150359890 | AN INTRAUTERINE DEVICE, AND A METHOD OF REDUCING THE RATE OF DIFFUSION OF ACTIVE INGREDIENTS IN SAID INTRAUTERINE DEVICE - An intrauterine device having at least one first pharmaceutically active ingredient and at least one first layer made of at least a first polymeric material, wherein between about 10 and about 60 v/v % of at least one particulate material is dispersed and/or incorporated in the first polymeric material. The presence of the particulate material will reduce the porosity of the polymer or otherwise obstruct the diffusion of the pharmaceutically active ingredient being released, thereby slowing its rate of release. In this way, it is possible to regulate the release rate and/or initial burst of the device, simply by adjusting the amount of particles/particulate material in the first layer, instead of having to adapt the size of the device to the desired release pattern, which requires expensive changes in production equipment and manufacturing processes. | 2015-12-17 |
20150359891 | NON-ADDICTIVE ANALGESIC SUSTAINED-RELEASE DRUG DELIVERY SYSTEM AND PREPARATION METHOD THEREOF - A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system. | 2015-12-17 |
20150359892 | STABLE COMPOSITIONS CONTAINING THROMBIN AND METHODS FOR PREPARATION AND USE THEREOF - Compositions comprising thrombin and collagen and methods of preparation thereof are disclosed herein. In one embodiment, a composition comprises thrombin and collagen in an aqueous buffer solution, wherein the buffer solution includes at least one of a first compound represented by Formula I: R | 2015-12-17 |
20150359893 | Acne formulation having stabilized ascorbic acid and other actives - The present invention provides for an acne formulation comprising an elastomer, dispersant, active and a drug and related methods of manufacture. | 2015-12-17 |
20150359894 | PROBIOTIC ORAL DOSAGE FORMS - Provided are probiotic compositions that have enhanced stability under various storage conditions. The stability of the probiotic compositions is enhanced through the addition of various agents and excipients. Examples of agents and excipients that may be used to enhance the stability of probiotic compositions include prebiotics, such as the sugar alcohols mannitol, sorbitol, and lactitol, and/or phytonutrients such as oligomeric proanthocyanidins (OPCs). The probiotic compositions may be formulated into oral dosage forms such as tablets, caplets, and capsules, or manufactured as a chewing gum or as a powder formulation that may be dissolved in a liquid such as water, milk, juice, or yogurt. | 2015-12-17 |
20150359895 | COPROCESSED SILICA COATED POLYMER COMPOSITION - The present invention provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises vinyl lactam derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared by a continuous process and has a Brookfield cohesion of less than 0.12 kPa, a bulk density of at least 0.249 gram/milliliter and a flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold. | 2015-12-17 |
20150359896 | COMPOSITIONS, METHODS AND DEVICES FOR LOCAL DRUG DELIVERY - This invention provide novel compositions, methods and devices for sustained drug delivery. The microencapsulated sustained drug delivery compositions are deposited using oscillating needle apparatus oscillating at 10-12000 minutes per minutes. The injected compositions may undergo variety of physical chemical changes upon deposition. The physical and chemical changes enables improved drug encapsulation and sustained drug release. Also described are new methods to form polymer microparticles or polymer films/implants in situ inside the tissue. The invention also describes colored biodegradable microparticle based compositions wherein the compositions comprise drug encapsulated microparticles and coloring agent encapsulated microparticles mixed in any proportion. Medical applications of the compositions and methods described in this invention are also described. | 2015-12-17 |
20150359897 | METHOD OF TREATING PATIENTS NON-RESPONSIVE TO PALONOSETRON - A method for treating chemotherapy-induced nausea and vomiting in individuals undergoing chemotherapy and previously treated with, and whom failed to respond to, a 5-HT3 antagonist other than granisetron is described. Individuals who fail to respond to, for example, palonosetron, as evidenced by an inadequate prevention or attenuation of acute or delayed chemotherapy-induced nausea and vomiting, are treated with a semi-solid drug delivery vehicle that provides a sustained release of granisetron. | 2015-12-17 |
20150359898 | Pemetrexed Complexes and Pharmaceutical Compositions Containing Pemetrexed Complexes - A complex comprises pemetrexed and a coformer. A pharmaceutical composition comprises a complex of pemetrexed and a co-former and one or more pharmaceutically acceptable excipients. | 2015-12-17 |
20150359899 | MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS - This invention relates to a peptide or polypeptide (a) which is esterified or thio-esterified (i) at the carboxylate of the C-terminus with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (ii) at a side-chain carboxylate of one or more Asp or Glu residues, if present, with a guanidinium alkanol, a guanidinium alkanethiol, a PEG substituted with a guanidinium group and having a free hydroxyl group, or a PEG substituted with a guanidinium group and a sulfhydryl group; (iii) at a hydroxyl group of one or more Ser, Thr or Tyr residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; (iv) at a sulfhydryl group of one or more Cys residues, if present, with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group; and/or (v) at the N-terminus with a guanidinium alkanoic acid or a PEG substituted with a guanidinium group and a carboxyl group, wherein said N-terminus is previously amidated with an alpha- or beta-hydroxy acid, and wherein the ester is formed between the hydroxy group of said alpha- or beta-hydroxy acid and the carboxylic group of said guanidinium alkanoic acid or said PEG substituted with a guanidinium group and a carboxyl group; and/or (b) which contains one or more disulfides, the disulfide being formed between the sulfhydryl group of a Cys reside, if present, and a guanidinium alkanethiol or a PEG substituted with a guanidinium group and a sulfhydryl group. | 2015-12-17 |
20150359900 | CONJUGATES OF WATER SOLUBLE POLYMER-AMINO ACID OLIGOPEPTIDE-DRUG, PREPARATION METHOD AND USE THEREOF - A conjugate of water soluble polymer-amino acid oligopeptide-drug of Formula (I) below and a pharmaceutical composition comprising the conjugate are provided. In the conjugate, P is a water soluble polymer; X is a linking group, wherein the linking group links P and A | 2015-12-17 |
20150359901 | PIPERAZINYL DERIVATIVE REDUCES HIGH-FAT DIET-INDUCED ACCUMULATION OF FAT IN THE LIVERS, THERAPEUTICALLY - A method for inhibiting a liver disease is provided. The method includes administering a pharmaceutical composition of one of a piperazine analogue and a piperazine analogue complex to a warm-blooded animal suffering from the liver disease. | 2015-12-17 |
20150359902 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG - Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound. | 2015-12-17 |
20150359903 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND MAYTANSINOIDS AS CYTOTOXIC AGENTS - The invention provides linker compounds containing a disulfide group, and maytansin-derived cytotoxic compounds that are useful for forming a CBA-drug conjugates, and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose. | 2015-12-17 |
20150359904 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS - The invention provides linker compounds and cytotoxic compounds that are useful for forming a CBA-drug conjugates; and conjugates so formed. Such conjugates and/or cytotoxic compounds may be effective for treating a range of diseases, such as cancer, with a relatively high activity at a relatively low, non-toxic dose. | 2015-12-17 |
20150359905 | COMPOSITION OF ANTI-ENDO180 ANTIBODIES AND METHODS OF USE FOR THE TREATMENT OF CANCER AND FIBROTIC DISEASES - The present invention provides antibodies or antigen-binding fragments thereof that specifically bind the ENDO | 2015-12-17 |
20150359906 | LIPIDS, LIPID COMPLEXES AND USE THEREOF - The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), | 2015-12-17 |
20150359907 | Functionalized DNA Dendrimers For Gene Delivery To Cells - Compositions are disclosed which comprise a DNA dendrimer having one or more DNA sequences linked thereto, the DNA sequences comprising DNA sequences encoding a polypeptide or regulatory RNA linked to DNA sequences that regulate expression of the DNA sequences encoding a polypeptide or regulatory RNA to produce an RNA coding for the polypeptide or to produce the regulatory RNA. Also disclosed are methods for treating diseases and conditions of cells by delivering the dendrimers to the cells, with subsequent expression of the encoded polypeptide or regulatory RNA. | 2015-12-17 |
20150359908 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE - Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion D | 2015-12-17 |
20150359909 | ORALLY ADMINISTERED BACTERIA AS VEHICLES FOR SYSTEMIC DELIVERY OF AGENTS - The current invention relates to the use of a bacterial species in the preparation of a composition adapted for oral administration for the delivery of an agent to a site in the body. The site in the body may be an organ or a tumour site. The bacterial species is a food grade, non-pathogenic, gram-positive bacteria capable of anaerobic growth. | 2015-12-17 |
20150359910 | TARGETING APTAMER FOR ATHEROSCLEROSIS AND PREPARATION METHOD AND APPLICATION THEREOF - Disclosed are a targeting aptamer for atherosclerosis and a preparation method and application thereof. The targeting aptamer is a targeting aptamer fragment for atherosclerosis obtained through screening of macrophage-derived foam cells together with reverse screening of smooth muscle cells, endothelial cells, and THP-1 cells using a SELEX method; and the use of the targeting aptamer in preparation of an MRI targeting nano-contrast agent for atherosclerosis allows the specific binding of the MRI targeting nano-contrast agent for atherosclerosis only with the macrophage-derived foam cells, and allows high specific binding thereof with vascular tissues with AS lesion, this improving targeting effect of the MRI targeting nano-contrast agent for atherosclerosis and realizing early specific diagnosis of arterial sclerosis. | 2015-12-17 |
20150359911 | Aptamer Specific to Integrin alpha-v-beta-3 and Use Thereof - The present invention relates to DNA aptamer specifically binding to integrin α | 2015-12-17 |
20150359912 | J-Aggregate Forming Nanoparticle - There is provided herein a nanovesicle having a bilayer comprising a saturated first phospholipid and no more than about 15 molar % of a second phospholipid covalently conjugated to a J-aggregate forming dye. | 2015-12-17 |
20150359913 | TETRAZINES/TRANS-CYCLOOCTENES IN SOLID PHASE SYNTHESIS OF LABELED PEPTIDES - This invention is in the field of labeled peptide construction for medical treatment and analysis. The invention relates to synthetic labeled peptide compositions, methods of synthesis, and methods of use for the synthetic labeled peptide compositions for medical treatment, imaging, and research purposes. | 2015-12-17 |
20150359914 | BILL STERILIZER EQUIPPED WITH COUNTING MACHINE - A bill sterilizer includes a counting machine having a bill input part, a bill sensing part and a bill discharge part; a body having an opening and a receiving space; a tray provided on the floor of the receiving space; an ion generator located on the wall surface of the receiving space; a door to block the opening of the receiving space; and a door lock located on the front face below the opening of the body to fix the door. The bill sterilizer equipped with the counting machine supplies cluster negative ions to the sterilizer body so that the cluster negative ions are evenly transferred to the surfaces of the bills after the whole counting machine for counting the number of the bills is located inside the bill sterilizer, thereby removing pollution sources of the bills. | 2015-12-17 |
20150359915 | PORTABLE UV DEVICES, SYSTEMS AND METHODS OF USE AND MANUFACTURING - Provided herein are portable ultraviolet (UV) devices, systems, and methods of use and manufacturing same. Methods of use include methods for UV disinfection and sterilization, more specifically, methods for UV disinfection and sterilization of a container, a room, a space or a defined environment. The portable UV devices, systems and methods are particularly useful for the UV disinfection and sterilization of a container, a room, a space or defined environment used in the food, beverage and dairy industry and in the process of fermentation for an alcoholic beverage. Provided are also portable UV devices, systems, and methods for inhibiting the growth of one or more species of microorganisms present in a container, a room, a space or a defined environment, preferably for inhibiting the growth of one or more species of microorganisms present on an interior surface of a container, a room, a space or a defined environment. | 2015-12-17 |
20150359916 | STABILIZED CHLORINE DIOXIDE FOR CONTAMINATION CONTROL IN ZYMOMONAS FERMENTATION - Though chlorine dioxide is generally used to control bacterial contamination, a method was developed which allows the use of stabilized chlorine dioxide (SCD) for controlling contamination during fermentation that uses the bacteria | 2015-12-17 |
20150359917 | METHODS FOR TREATING ODORS - There are provided methods for treating a fluid having an undesirable odor. The methods comprise contacting the fluid with a H | 2015-12-17 |
20150359918 | Organic Waste Odor Absorber - An organic waste odor absorbing composition for the absorption of odors resulting from decomposing organic waste is disclosed. The composition comprises dried carbon and/or silica based matter, either natural or synthetic. The carbon-based materials consist of 35% to 85% holocellulose and 8% to 30% lignin. The silica-based materials consist of 40% to 80% silica. The materials may be mechanically sized to allow for adequate airflow and surface area exposure to the organic waste. | 2015-12-17 |
20150359919 | INLINE AIR TREATMENT DEVICE - An airflow treatment device configured to be installed inline in the ductwork of an air handling system (e.g., HVAC system) in a manner that is substantially free of obstructing the airflow through the ductwork or requiring any supplemental power to treat the airflow passing by the treatment device. The disclosed airflow treatment device can also be maintained substantially free of any interruptions, disassembly or downtime to the air handling system after initial inline installation of the disclosed device. In one arrangement, the airflow treatment device is capable of accepting a threaded odor neutralizer container at its base. Ductwork need only be disassembled once to attach the disclosed device inline in the airflow path of the ductwork. When the odor neutralizing agent needs replenished, the container can be detached from the device, replenished, and reattached to the device free of disruption to the air flow of the air handling system. | 2015-12-17 |
20150359920 | FINE PARTICLE DIFFUSION DEVICE - A fine particle diffusion device includes: a first outlet ( | 2015-12-17 |
20150359921 | System and Method For Reducing Airborne Contamination - A system for reducing airborne contamination includes a housing defining the structure of the system and configured to fit within a window of a building. The system also includes a variable-speed fan, and a microprocessor in communication with the fan and configured to control the speed of the fan. Within the housing, the system may include an electrical chassis that defines a chamber and supports at least some of the system's electrical components within the housing. A removable cartridge may be selectively coupled with the electrical chassis to form a germicidal radiation chamber within the housing and within an airflow path through the system. The removable cartridge includes UV light source(s) and filter(s) that sterilize the air as it passes through the system and the germicidal radiation chamber. | 2015-12-17 |
20150359922 | AIR PURIFYING APPARATUS USING ULTRA VIOLET LIGHT EMITTING DIODE - The present invention relates to an air cleaning apparatus comprising a UVLED, which can efficiently clean air flowing in tubes by an effective combination of the UVLED and a photocatalyst and can effectively clean air flowing in a duct by enhancing the cleaning function or increasing the number of cleaning steps when the concentration of harmful substances increases. The air cleaning apparatus includes: a case comprising an inlet configured to introduce air, an outlet configured to discharge air, and a duct disposed between the air inlet and the air outlet; a photocatalyst unit disposed in the duct; and a UVLED module disposed in the duct and including a plurality of first UVLEDs arranged to irradiate UV light from the side of the inlet to the side of the outlet. | 2015-12-17 |
20150359923 | Method Of Manufacturing Biodegradable Materials For Filling Nasal Cavity - A method of manufacturing biodegradable materials for filling nasal cavity of the present invention comprises the following steps: a. within a predetermined temperature range, evenly mixing chitosan and the substrate (starch or cellulose) to make a first solution; b. adding crosslinking agent in the first solution for crosslinking reaction; c. pouring the first solution into the mold; d. removing water through freeze-drying process, thereby the biodegradable materials for filling nasal cavity are obtained. The biodegradable materials are filled in patient's nasal cavity to stop bleeding and avoid a second time injury by removing, because of biodegradable absorption. | 2015-12-17 |
20150359924 | TISSUE ADHESIVE AND METHOD FOR PRODUCING SAME - There is provided a tissue adhesive to be applied to a tissue by mixing an adhesive component including an aqueous solution of a fish-derived gelatin with a curable component including an aqueous solution of a water-soluble crosslinking reagent, wherein the water-soluble crosslinking reagent has an amide linkage or an ethylene glycol unit or a sugar chain in the molecular main chain thereof and has two or more of an active ester group or an acid anhydride or an aldehyde group. | 2015-12-17 |
20150359925 | Procoagulant Peptides and Their Derivatives and Uses Therefor - The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof. | 2015-12-17 |
20150359926 | Methods And Compositions For Medical Articles Produced From Proteinaceous Compounds - The invention disclosed herein provides compositions and methods for biocompatible biomaterials with improved control of microorganisms, improved biocompatibility, lower toxicity, and reduce vCJD transmission potential. These combined benefits cascade to provide improved efficacy, improved patient compliance and improved performance, while limiting clinical complications in treatment. | 2015-12-17 |
20150359927 | HYDROGEL IMPLANTS WITH VARYING DEGREES OF CROSSLINKING - The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions. | 2015-12-17 |
20150359928 | VISCOELASTIC HYDROGELS WITH FAST STRESS RELAXATION - Provided are fast relaxing hydrogels that are useful for regulating cell behavior and enhancing tissue regeneration, e.g., bone regeneration. | 2015-12-17 |
20150359929 | Mechanochemical Collagen Assembly - Methods and devices are described for using a controlled extensional strain to organize prefibrillar collagen and/or elastin solutions into an organized array of fibrils. The organized array of collagen fibrils produced by the disclosed methods and devices can be used for tissue engineering applications. | 2015-12-17 |
20150359930 | COATED INTRAOCULAR LENS AND ITS MANUFACTURE - An intraocular lens has a hydrophobic lens body ( | 2015-12-17 |
20150359931 | Calcium-Mediated Effects of Coral and Methods of Use Thereof - This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions. | 2015-12-17 |
20150359932 | Extracellular Matrix Constructs for Treating Damaged Biological Tissue - Extracellular matrix (ECM) constructs having a biodegradable support scaffold and an anchoring mechanism, which includes a plurality of biodegradable microneedles that are capable of piercing tissue and anchoring therein. In a preferred embodiment, the support scaffold and anchoring mechanism comprise an ECM material. In some embodiments, the microneedles are also capable of administering a biologically active agent and/or a pharmacological composition to the engaged tissue. | 2015-12-17 |
20150359933 | Extracellular Matrix Constructs for Treating Damaged Biological Tissue - Extracellular matrix (ECM) constructs having a biodegradable support scaffold and an anchoring mechanism, which includes a plurality of biodegradable microneedles that are capable of piercing tissue and anchoring therein. In a preferred embodiment, the support scaffold and anchoring mechanism comprise an ECM material. In some embodiments, the microneedles are also capable of administering a biologically active agent and/or a pharmacological composition to the engaged tissue. | 2015-12-17 |
20150359934 | Articles for Tissue Regeneration with Biodegradable Polymer - The invention is also directed to particulate articles comprising extracellular matrix components that are encased in a biodegradable polymer composition. Methods of for treating damaged tissue and regenerating new tissue at sites of the damaged tissue by placing a particulate article in mammals are claimed. | 2015-12-17 |
20150359935 | Extracellular Matrix Encasement Structures and Methods - A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue. | 2015-12-17 |
20150359936 | Extracellular Matrix Encasement Structures and Methods - A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue. | 2015-12-17 |
20150359937 | Extracellular Matrix Encasement Structures and Methods - A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue. | 2015-12-17 |
20150359938 | Extracellular Matrix Encasement Structures and Methods - A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue. | 2015-12-17 |
20150359939 | Extracellular Matrix Encasement Structures and Methods - A bioremodelable encasement structure comprising a pouch formed from at least one sheet of bioremodelable material, the pouch including an internal region that is configured to receive a device therein, the bioremodelable material comprising mesothelial tissue. | 2015-12-17 |
20150359940 | METHODS, SUBSTRATES, AND SYSTEMS USEFUL FOR CELL SEEDING OF MEDICAL GRAFTS - Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof. | 2015-12-17 |
20150359941 | METHOD FOR PROCESSING CANCELLOUS BONE MATERIAL AND RELATED PRODUCTS, METHODS AND USES - Cancellous bone material may be processed in a portable container apparatus to prepare a stromal vascular fraction concentrate. Cancellous bone material may be washed to remove non-bone material, digested and digested material centrifuged, with all operations being performed on cancellous bone material while disposed in the portable container apparatus. Uncultured stromal vascular fraction cells separated from enzyme-digested cancellous bone material, and which contain osteoblasts and osteoclasts, may be removed from the portable container and used without culturing for a variety of medical applications. Medical treatment compositions may be prepared including recovered stromal vascular fraction cells and scaffold material. | 2015-12-17 |
20150359942 | Extracellular Matrix (ECM) Structures for Tissue Regeneration - A multi-sheet extracellular matrix (ECM) structure for tissue regeneration, the ECM structure having joined first and second ECM sheet members and an agent dispersal network disposed between the sheets, the dispersal network being configured to receive and transfer a bioactive agent through the network and, when the ECM structure is attached to tissue, administer the bioactive agent to the tissue. | 2015-12-17 |
20150359943 | PDLLA STENT COATING - An amorphous PDLLA stent coating for drug delivery is disclosed. | 2015-12-17 |
20150359944 | COATING AGENTS AND COATED ARTICLES - The invention describes novel coating agents that include a polymer, one or more latent reactive groups and one or more noncovalent linking groups, the noncovalent linking groups selected to interact with a substrate to which the coating agent is applied. The coating agents are useful for providing a coating that can be further functionalized (for example, by | 2015-12-17 |
20150359945 | ANTIMICROBIAL COATINGS - Provided are polymer-based surfaces (e.g., gloves) with an antimicrobial coating, e.g., comprising chlorhexidine and a partially hydrolyzed polyvinyl acetate copolymer, or a biguanide and a silicone. Methods of coating polymer-based surfaces with antimicrobial compositions are also provided. | 2015-12-17 |
20150359946 | COATINGS FOR THE CONTROLLABLE RELEASE OF ANTIMICROBIAL METAL IONS - Antimicrobial metal ion coatings. In particular, described herein are coatings including an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, niobium or rhenium) on a substrate so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is exposed to a bodily fluid. The anodic metal may be at least about 25 percent by volume of the coating, resulting in a network of anodic metal with less than 20% of the anodic metal in the coating fully encapsulated by cathodic metal. | 2015-12-17 |
20150359947 | PLASTICIZERS FOR A BIODEGRADABLE SCAFFOLDING AND METHODS OF FORMING SAME - Methods of making polymeric devices, such as stents, with one or more modifications such as addition of plasticizers, to improve processing, and the devices made by these methods. | 2015-12-17 |
20150359948 | MEDICAL DEVICE WITH INTRAPORE FILMS - The present disclosure relates to a medical device and methods of making the same. The medical device includes a porous substrate and at least one film. The film is formed within the pore of the substrate. The film is intra-porous and does not contact adjacent pores or films. | 2015-12-17 |
20150359949 | Polyp Filter - A polyp filter is non-integral to a corresponding suction-line dedicated polyp track. By one approach this polyp filter has a threaded portion that threadably engages at least one of a suction-line dedicated polyp trap housing and lid. That threaded portion can comprise, for example, a threaded hole that is formed axially through the polyp filter. By one approach that threaded portion threadably engages a threaded tube as comprises a part of the lid. | 2015-12-17 |
20150359950 | SELF-CLEANING SURGICAL SUCTION DEVICE AND METHOD OF USE - A surgical suction device is disclosed that includes a suction tube having a first longitudinal axis, a proximal opening, and a distal opening; a guide tube that is substantially coextensive with and parallel to the suction tube, and has a second longitudinal axis, a proximal opening, and a distal opening; a stylet having a proximal end and a distal end; and a junction point having a proximal opening and a distal opening; wherein the stylet is disposed along the second longitudinal axis and encircled by the guide tube, and urging the stylet through the guide tube along the second longitudinal axis through the junction conduit translates the distal end of the stylet to the distal opening of the junction point. The guide tube may effectively cut the length of the handle member in half. | 2015-12-17 |
20150359951 | SUCTION DEVICE - The present invention relates to a suction device. The suction device comprises an attachment portion adapted to be attached to a wound cover member. The suction device comprises a fluid inlet which is at least partially circumscribed by the attachment portion. The suction device also comprises a fluid outlet. The suction device further comprising a connection portion adapted to, at least during one operation condition of the suction device, provide a fluid communication between the fluid inlet and the fluid outlet. The connection portion comprises an inspection portion that is transparent to thereby facilitate the positioning of the suction device relative to the wound cover member. | 2015-12-17 |
20150359952 | CONNECTOR RING CLAMP AND ASSOCIATED METHODS OF USE - In one embodiment, the present invention includes a connector ring assembly to attach a VAD to a heart. The assembly includes a clamp which can rotate completely about the annular wall in a first state and is fixed relative to the annular wall in a second state. The clamp transitions from the first state to the second state via an actuator. The actuator can be configured with an axis of rotation generally parallel to the opening of the annular wall, thereby allowing manipulation of the actuator through the same surgical accessway as that used to implant the connector ring assembly. At least one embodiment provides a connector flange separately from an annular wall to provide greater access to the connector flange during implantation. The annular wall and clamp are attached to the connector flange after the flange is fixed to the heart. | 2015-12-17 |
20150359953 | DIALYZER COMPRISING A BUNDLE OF HOLLOW FIBERS AND METHOD FOR PRODUCING SUCH HOLLOW FIBER - A dialysis membrane and a hollow fiber as pre-product as well as a method for producing the hollow fiber are disclosed. The dialysis membrane includes a distribution of the pore sizes which follows an exponential function such as an e-function. The inverse value of the exponential coefficient (K) is at least 30 nm | 2015-12-17 |
20150359954 | AUTHENTICATION SYSTEM UTILIZED IN A SORBENT-BASED DIALYSIS SYSTEM FOR THERAPY OPTIMIZATION - A dialysis authentication and management system comprising at least one dialysis component having at least one authentication component affixed thereon. The dialysis component can be any one of a dialyzer, sorbent cartridge, recharger or any other dialysis component. The authentication component can be selected from the group of a radio-frequency identification marker, a bar code, a one-wire security component, and a wireless authentication component. The authentication system can ensure that all components used are in proper usable condition and/or certified. The system can also manage the recharging of rechargeable components, and optionally manage dialysis therapy. | 2015-12-17 |
20150359955 | SUBSTITUTION FLUID PUMP INTEGRATED IN A DIALYSIS MACHINE - A dialysis machine comprising internal fluidics, wherein the internal fluidics includes a dialysis fluid pump for pumping dialysis fluid from a dialysis fluid reservoir through a dialysis fluid feed line to a dialyzer and from the dialyzer through a dialysis fluid drain line to a waste reservoir, a substitution fluid pump for supplying dialysis fluid through a substitution fluid feed line as substitution fluid to an extracorporeal hose system including ports on the patient side and coupling means for connecting the extracorporeal hose system to the internal fluidics is disclosed. | 2015-12-17 |
20150359956 | FLUID PUMPING APPARATUS FOR USE WITH A REMOVABLE FLUID PUMPING CARTRIDGE - The present invention involves, in some embodiments apparatus, such as dialysis apparatus, and methods for pumping fluid. Certain embodiments comprise a housing enclosing a pump drive assembly for actuating at least one pump on a removable fluid pumping cassette. The housing may comprise a door connected to the housing for enclosing an installed cassette in the housing upon closure of the door. The pump drive assembly may comprise a mating block configured for operative association with an installed cassette and may be configured to permit a sealing engagement with an installed cassette upon closure of the door. To facilitate sealing, certain embodiments of the door include a movable compression plate configured to exert a compressive force on an installed cassette against the mating block when the door is in a closed position. | 2015-12-17 |
20150359957 | AXIALLY SPLIT FOAM PERITONEAL DIALYSIS CATHETER DESIGN WITH FUNCTIONAL COATINGS - The present disclosure provides a dialysis device for peritoneal dialysis. The device comprises a proximal tubular portion comprising a plurality of proximal lumens and a distal tubular portion comprising a plurality of independent tubes. Each independent tube has a distal lumen that is in fluid communication with one of the proximal lumens for delivery and retrieval of dialysis solution. The independent tubes are individually flexible and positionable with in the patient's body to aid in enhanced retainment of the device. The device also comprises one or more coatings. The coatings may be disposed on the entire device or a portion of the device to aid in reducing inflammation, irritation, leaking, or infection experienced during peritoneal dialysis. | 2015-12-17 |
20150359958 | METHOD FOR STERILIZATION OF A HOLLOW FIBER FILTER MODULE, HOLLOW FIBER FILTER MODULE COMPRISING A CLOSURE, AND OXYGEN ABSORBING CLOSURE - Methods of sterilizing a hollow fiber filter module, hollow fiber filter modules comprising closures and closures comprising an oxygen absorber are disclosed. A method according to the invention is distinguished in that the interior of the hollow fiber filter module is sealed off by means of the housing associated to the hollow fiber filter module and by means of the closures, and at least one of the closures comprises an oxygen absorber. A hollow fiber filter module according to the invention is characterized by the corresponding closures with or without an oxygen absorber. | 2015-12-17 |
20150359959 | Method For Delivering Desired Light Dose To Cells In A Light Attentuating Medium - A method provided for determining a range for the amount of light-energy attenuating material that may be present in a suspension containing target cells (such as MNCs), light-energy attenuating matter (such as RBCs and plasma), and a light-energy activatable compound (such as psoralen) so that a desired therapeutic effect (such as the percentage of MNCs in which apoptosis occurs) is obtained when the suspension is subjected to a known amount of light energy. In a related aspect, a method is provided for preparing a suspension containing target cells, light-energy attenuating matter, and a light-energy activatable compound so that a desired therapeutic effect is obtained when the suspension is subjected to a known amount of light energy | 2015-12-17 |
20150359960 | User-Actuated Storage Assembly For Injection Device - A storage assembly is removably connectable to a drug delivery device. A first chamber is disposed in the housing. A plurality of penetrating members are stored in the first chamber. A second chamber is disposed in the housing for storing the plurality of penetrating members after being used in an injection. A transfer drum disposed in the housing transfers one of the penetrating members from the first chamber to an injection position and from the injection position to the second chamber following an injection. | 2015-12-17 |
20150359961 | BOTTLE SUPPORT FOR AN INJECTION OR INFUSION DEVICE - A bottle support for an injection or infusion device with a main body, which has at least one bottle holder for the holding of a neck of a supply bottle. In order to bring about as simple and quick an equipping as possible of the injection device with supply bottles with different sizes and to hold the supply bottles securely in the bottle support, provision is made so that a shaft is formed in the main body, in which a tension slide, pretensioned with a spring, is supported so it can be displaced linearly. In a first position, the tension slide locks the neck of the supply bottle, and in a second position, the neck of the supply bottle is released. | 2015-12-17 |
20150359962 | Multiple Infusion Channel Data Graphical User Interface - Data is received that characterizes infusions administered to a patient among each of a plurality of infusion channels. Thereafter, a plurality of infusion events and respective event times are identified based on the received data. A temporal view of the infusion events can then be displayed in a graphical user interface and/or the temporal view of the infusion events can form part of a report. The temporal view segregates each channel into a separate swim lane with each swim lane visualizing infusion events for the corresponding channel at the respective event times. Related apparatus, systems, techniques and articles are also described. | 2015-12-17 |
20150359963 | Drug Infusion System and Method - An actuator for an infusion drive mechanism comprises a piston defining a first axis and being movable within a passageway of the infusion drive mechanism to convey at least one infusion medium. The passageway defines a longitudinal axis. An armature is connected to the piston and defines at least one cavity configured for disposal of a biasing member engageable with a surface of the infusion drive mechanism to orient the first axis transverse relative to the longitudinal axis. Systems and methods of use are disclosed. | 2015-12-17 |
20150359964 | INTRAVENOUS LINE FLOW SENSOR FOR ADVANCED DIAGNOSTICS AND MONITORING IN EMERGENCY MEDICINE - A portable medical device having an intravenous line flow sensor integrated into a cable. The portable medical device may be a defibrillator having an ECG or electrode cable couple to ECG or electrode leads. The flow sensor may be integrated into the ECG or electrode cable. The portable medical device uses the flow sensor to capture and store information about fluids delivered to a patient being treated with the portable medical device. The information may include total volume provided, flow rate, and the like. The information may then be used to evaluate the treatment provided to the patient. | 2015-12-17 |
20150359965 | FLUID RESTRICTION MECHANISMS FOR DRUG DELIVERY PUMPS - A replaceable fluid restriction mechanism includes: an aperture residing adjacent to a fluid pathway connection and configured to permit flow of a drug fluid through the aperture when the fluid pathway connection is open; an entry point of a fluid channel configured such that the flow of drug fluid can travel through aperture to the entry point and through the fluid channel to an exit point; and an outlet aperture of a port through which the flow of drug fluid may travel after exiting the exit point, wherein a fluid conduit is connected to the fluid restriction mechanism at the outlet aperture. A configurable fluid restriction mechanism includes a plurality of fluid channels, selectable to align with the entry point and an exit point of the fluid restriction mechanism. | 2015-12-17 |
20150359966 | SYSTEM FOR MONITORING AND DELIVERING MEDICATION TO A PATIENT AND METHOD OF USING THE SAME TO MINIMIZE THE RISKS ASSOCIATED WITH AUTOMATED THERAPY - A system and method for monitoring and delivering medication to a patient. The system includes a controller that has a control algorithm and a closed loop control that monitors the control algorithm. A sensor is in communication with the controller and monitors a medical condition. A rule based application in the controller receives data from the sensor and the closed loop control and compares the data to predetermined medical information to determine the risk of automation of therapy to the patient. A system monitor is also in communication with the controller to monitor system, remote system, and network activity and conditions. The controller then provides a predetermined risk threshold where below the predetermined risk threshold automated closed loop medication therapy is provided. If the predetermined risk threshold is met or exceeded, automated therapy adjustments may not occur and user/clinician intervention is requested. | 2015-12-17 |